Form D · Biotechnology
NEW YORK GLOBAL INNOVATIONS INC.
New York, NY · CIK 0001062128
Offering snapshot reported Sep 7, 2016 · SEC filing
- Reported sold
- $500K Offering amount: $500K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $500K Reported outside-investor minimum
- First sale
- Aug 23, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 7, 2016 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Feb 23, 2010 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Apr 22, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 12, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-270161
Source: Form D, filed Sep 7, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Israel Alfassi | Director |
| Yaron Meerfeld | Director, Executive |
| Chanan Morris | Executive |
| Gadi Peleg | Director |
| Randy F. Rock | Director |
| David W. Sass | Director |
| Pierre L. Schoenheimer | Director |
| Peker Tzlil | Executive |
| Dana Wolf | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
18 East 16 Th Street, Suite 307
New York, NY, 10003
New York, NY, 10003